NCAPH as an onco-structural hub linking chromatin architecture to metabolic reprogramming, immune evasion, and therapy resistance.

Chromatin architecture is increasingly recognized as a fundamental regulatory layer that enables cancer cells to integrate genetic instability, transcriptional plasticity, metabolic adaptation, and immune escape. NCAPH, a non-SMC regulatory subunit of the condensin I complex, has long been regarded as a mitosis-associated chromosome condensation factor. However, accumulating evidence across multiple cancer types reveals that NCAPH plays far broader roles in malignant progression and therapeutic resistance. In this review, we synthesize recent advances to position NCAPH as an onco-structural hub that links higher-order chromatin organization to genome stability, metabolic reprogramming, immune evasion, and therapy resistance. We first summarize the biological features of NCAPH within the condensin I system and highlight its dosage-sensitive effects on chromatin mechanics and DNA damage response. We then integrate pan-cancer evidence demonstrating that NCAPH overexpression is associated with aggressive clinicopathological features, poor prognosis, immune suppression, and resistance to chemotherapy, targeted therapy, radiotherapy, and immune checkpoint blockade. Mechanistically, NCAPH-mediated chromatin remodeling supports glycolytic and anabolic metabolism, stabilizes immune checkpoint signaling such as PD-L1, sustains stemness and epithelial-mesenchymal plasticity, and enables adaptive tolerance to genotoxic and immunological stress. Finally, we discuss the translational implications of targeting the NCAPH axis, including its potential as a biomarker for patient stratification and as a therapeutic vulnerability for rational combination strategies. By integrating structural genome biology with cancer metabolism and tumor immunology, this review provides a unifying framework for understanding how chromatin architectural regulators drive malignant fitness and highlights key challenges and future directions for exploiting NCAPH-mediated chromatin adaptability in precision oncology.